Human Vascular Endothelial Growth Factor Receptor 3 (FLT4) Enzyme
234€ (2 µg)
Por favor contáctenos para obtener información detallada sobre el precio y disponibilidad.
935106861
info@markelab.com
name
Human Vascular Endothelial Growth Factor Receptor 3 (FLT4) Enzyme
category
Proteins and Peptides
provider
Abbexa
reference
abx073884
tested applications
SDS-PAGE
Description
Vascular Endothelial Growth Factor receptor-3 Protein is a recombinant protein kinases.
Documents del producto
Instrucciones
Data sheet
Product specifications
| Category | Proteins and Peptides |
| Immunogen Target | Vascular Endothelial Growth Factor Receptor 3 (FLT4) |
| Host | Insect |
| Recommended Dilution | Optimal dilutions/concentrations should be determined by the end user. |
| Origin | Human |
| Expression | Recombinant |
| Purity | > 90% (SDS-PAGE) |
| Size 1 | 2 µg |
| Size 2 | 10 µg |
| Size 3 | 1 mg |
| Form | Lyophilized |
| Tested Applications | SDS-PAGE |
| Availability | Shipped within 5-10 working days. |
| Dry Ice | No |
| UniProt ID | P35916 |
| Alias | PCL,CHTD7,FLT-4,FLT41,LMPH1A,LMPHM1,VEGFR3,VEGFR-3,Tyrosine-protein kinase receptor FLT4,Fms-like tyrosine kinase 4,Vascular endothelial growth factor receptor 3 |
| Background | Protein FLT4 |
| Status | RUO |
| Note | This product is for research use only. Not for human consumption, cosmetic, therapeutic or diagnostic use. |
Descripción
Fms related receptor tyrosine kinase 4 (FLT4) FLT4, also known as vascular endothelial growth factor receptor 3 (VEGFR3), is a receptor tyrosine kinase critical for the regulation of lymphangiogenesis, the formation of lymphatic vessels. Structurally, FLT4 comprises an extracellular domain with seven immunoglobulin-like loops, a single transmembrane domain, and an intracellular tyrosine kinase domain. FLT4 binds VEGF-C and VEGF-D ligands, leading to receptor dimerization and activation of downstream signaling pathways, including the MAPK and PI3K-AKT cascades. These pathways are essential for lymphatic endothelial cell proliferation, migration, and survival. FLT4 is predominantly expressed in lymphatic endothelial cells, where it plays a pivotal role in maintaining lymphatic vessel integrity and fluid homeostasis. Dysregulation of FLT4 has been linked to lymphedema, a condition characterized by lymphatic fluid accumulation, and its overexpression has been implicated in cancer progression, where it promotes tumor lymphangiogenesis and metastasis. FLT4 is a promising therapeutic target for modulating lymphatic function in both pathological and developmental contexts.
Related Products
Human FLT4(Vascular endothelial growth factor receptor 3) ELISA Kit
Ver Producto
Mouse VEGFR3/FLT4(Vascular Endothelial Cell Growth Factor Receptor 3) ELISA Kit
Ver Producto